IC
SCPH

Ikarian Capital’s scPharmaceuticals SCPH Stock Holding History

Ikarian Capital’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,647
Closed -$133K – 173
2023
Q3 		$133K Sell
18,647
-131,353
-88% -$1.03M 0.02% 125
2023
Q2 		$1.53M Buy
+150,000
New +$1.57M 0.24% 75
2022
Q4 		– Sell
-479,383
Closed -$3.13M – 104
2022
Q3 		$3.13M Sell
479,383
-404,625
-46% -$2.16M 0.62% 49
2022
Q2 		$4.26M Sell
884,008
-86,090
-9% -$426K 0.78% 41
2022
Q1 		$5.51M Buy
970,098
+68,736
+8% +$338K 0.72% 39
2021
Q4 		$4.53M Hold
901,362
– – 0.67% 39
2021
Q3 		$5.99M Sell
901,362
-193,662
-18% -$1.16M 0.42% 57
2021
Q2 		$6.69M Sell
1,095,024
-213,675
-16% -$1.29M 0.54% 53
2021
Q1 		$8.7M Sell
1,308,699
-157,448
-11% -$1.08M 0.29% 77
2020
Q4 		$7.76M Sell
1,466,147
-15,000
-1% -$117K 0.34% 69
2020
Q3 		$11M Buy
1,481,147
+12,500
+0.9% +$97.7K 0.8% 36
2020
Q2 		$10.8M Buy
1,468,647
+395,000
+37% +$3.47M 0.86% 37
2020
Q1 		$7.95M Buy
+1,073,647
New +$7.79M 0.6% 42

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Ikarian Capital's SCPH Position: Q4 2023 in Review

Ikarian Capital sold out of scPharmaceuticals (SCPH) in Q4 2023, closing a stake of 18,647 shares — an estimated $133K sold.

Ikarian Capital first reported a position in SCPH in Q1 2020 and held it in 13 quarters. The position peaked at $11M in Q3 2020. 81 funds tracked by Wall St. Rank hold SCPH as of Q4 2023.

  • Ikarian Capital reported no remaining scPharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Ikarian Capital sold 18,647 scPharmaceuticals shares in Q4 2023, an estimated $133K.
  • Ikarian Capital first reported a position in scPharmaceuticals in Q1 2020 and held it in 13 quarters.
  • Ikarian Capital's scPharmaceuticals position peaked at $11M in Q3 2020.
  • 81 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2023.

Based on Ikarian Capital's 13F filing for Q4 2023, filed 14 Feb 2024.